May 25 • 1 min read

PRO: Mind Medicine Earnings Report Breakdown

Psychedelic Invest’s very own Adam Tubero digs into Mind Medicine’s ($MNMD) LSD program, Ibogaine, and the company’s Q1 2022 earnings report. Adam explains why his sentiment around MNMD has started to shift lately. Are you bullish or bearish? Leave your comments over on the Psychedelic Invest YouTube channel.

You must have PRO to access this content.

Become a Pro

Do you want to know more about these companies?

MNMD MindMed

PRO: Mind Medicine Earnings Report Breakdown

Do you want to know more about these companies?

Track the entire psychedelic market using the only index that covers the entire psychedelics marketplace.

Nucleus Ecosystem

PRO: Mind Medicine Earnings Report Breakdown

Do you want to know more about these companies?

Track the entire psychedelic market using the only index that covers the entire psychedelics marketplace.

Related Articles

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy